Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Advent Life Sciences is a venture capital firm founded in 2006 and headquartered in London, UK. The firm emerged as a spin-out from Advent Venture Partners, initiated by co-founders Raj Parekh and Shahzad Malik. Advent Life Sciences focuses on building innovative life sciences businesses across the UK, Europe, and the USA. The firm has successfully guided numerous companies from concept through clinical trials and regulatory approval, achieving a total of 15 product approvals across its portfolio.
Currently, Advent Life Sciences manages approximately $285 million in assets under management (AUM) and has completed two significant funds, with Fund II closing at £145.5 million ($235 million) and Fund III reported at $285 million. The firm operates with a team of around 18 investment professionals, leveraging their expertise to support early and mid-stage companies in the biotech, pharma, medtech, and digital health sectors.
Advent Life Sciences invests primarily in the sectors of biotech, healthcare, and digital health, with a strong emphasis on new drug discovery, medical technology, enabling technologies, and vaccines. The firm typically engages with companies at the Seed stage or Series A, employing a first-in-class or best-in-class investment approach. This strategy allows Advent to support innovative companies that are translating breakthrough science into approved medicines or medical products.
The geographic focus includes the UK, Europe, and the USA, enabling Advent Life Sciences to tap into diverse markets and innovative research hubs. The firm looks for founders who demonstrate a strong vision and capability to navigate the complexities of bringing new therapies to market. Advent Life Sciences provides strategic guidance throughout the development process, ensuring that portfolio companies can achieve their milestones effectively.
Advent Life Sciences has a diverse portfolio of 15 companies, showcasing its commitment to advancing life sciences. Notable portfolio companies include:
In addition to these active companies, Advent Life Sciences has achieved notable exits, including:
Raj Parekh – Co-founder and General Partner. Raj has extensive experience in venture capital and has led numerous successful investments in the life sciences sector.
Shahzad Malik – Co-founder and General Partner. Shahzad has a strong background in building and managing life sciences companies, contributing to Advent's strategic direction.
Kaasim Mahmood – General Partner. Kaasim specializes in biotech investments and has a track record of supporting innovative companies in the sector.
Dominic Schmidt – General Partner. Dominic brings expertise in medical technology and has been instrumental in guiding portfolio companies through development.
Satish Jindal – General Partner. Satish has a background in pharmaceuticals and focuses on investments that drive innovation in drug discovery.
Katrine Bosley – Venture Partner. Katrine has significant experience in biotech and has held leadership roles in various life sciences companies.
Don Drakeman – Venture Partner. Don has a strong track record in the life sciences sector, particularly in drug development and commercialization.
Alain Huriez – Venture Partner. Alain specializes in medical technologies and has extensive experience in guiding startups through regulatory processes.
Majid Kazmi – Clinical Advisor. Majid provides clinical insights and guidance to portfolio companies, ensuring alignment with healthcare standards.
Simon Kerry – Operating Partner. Simon supports operational aspects of portfolio companies, helping them scale effectively.
Philomena Lip – Principal. Philomena focuses on sourcing and evaluating new investment opportunities in the life sciences sector.
Roy Lobb – Venture Partner. Roy has a wealth of experience in venture capital and supports portfolio companies in strategic planning.
Jon Moore – Operating Partner. Jon assists portfolio companies with operational challenges and growth strategies.
Fraser Murray – Head of Scientific Evaluation. Fraser evaluates scientific merit in potential investments, ensuring alignment with Advent's focus areas.
Ian J. Nicholson – Operating Partner. Ian provides operational support and strategic guidance to portfolio companies.
John Rex – Operating Partner. John focuses on helping portfolio companies navigate regulatory challenges.
Alan E. Walts – Venture Partner. Alan has extensive experience in the life sciences sector and supports investment decisions.
Gwen O'Driscoll – Analyst. Gwen assists in research and analysis of potential investment opportunities.
Rowena Patel – Financial Director. Rowena oversees financial operations and reporting for Advent Life Sciences.
Victoria Smith – Financial Controller. Victoria manages financial controls and compliance within the firm.
Tom Wigmore – Accounts Assistant. Tom supports the accounting team in financial management.
Bonita Theara – Executive Assistant. Bonita provides administrative support to the partners and team.
Andrea Beesley – Team Assistant. Andrea assists with various operational tasks within the firm.
To pitch Advent Life Sciences, founders should send an email to contact@adventls.com. It is recommended to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. Advent Life Sciences values clarity and detail in presentations, so founders should be prepared to discuss their technology and its potential impact on the market.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, but cold emails are also accepted.
In recent months, Advent Life Sciences has been active in the life sciences sector, with notable developments from its portfolio companies. In March 2023, Levicept received FDA acceptance for an IND application for a potential treatment for osteoarthritis, marking a significant milestone in its development.
Additionally, Beacon Therapeutics successfully closed an oversubscribed Series C financing round in April 2023, raising over $75 million to advance its ocular gene therapy initiatives. These developments highlight Advent's commitment to supporting innovative companies in achieving their milestones.
What are Advent Life Sciences' investment criteria?
Advent Life Sciences primarily invests in early to mid-stage companies within the biotech, healthcare, and digital health sectors. They focus on new drug discovery, medical technology, and enabling technologies, typically engaging at the Seed or Series A stages.
How can I apply or pitch to Advent Life Sciences?
Founders can pitch Advent Life Sciences by sending an email to contact@adventls.com. It is advisable to include a detailed pitch deck outlining the business model, market opportunity, and team background.
What makes Advent Life Sciences different from other investors?
Advent Life Sciences distinguishes itself through its deep expertise in the life sciences sector and its commitment to guiding companies from concept through regulatory approval. The firm has a proven track record of successful product approvals and exits.
What is Advent Life Sciences' geographic scope?
The firm invests primarily in the UK, Europe, and the USA, allowing it to leverage diverse markets and innovative research environments.
What is the typical check size for investments?
While specific check sizes are not disclosed, Advent Life Sciences typically invests in early-stage companies, which often involves smaller initial investments that can grow as companies progress through their development stages.
What kind of post-investment involvement does Advent Life Sciences have?
Advent Life Sciences provides strategic guidance and support throughout the development process, helping portfolio companies navigate the complexities of bringing innovative therapies to market.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.